{'52WeekChange': 0.56071424,
 'SandP52WeekChange': 0.0644362,
 'address1': 'Three International Towers',
 'address2': 'Level 24 300 Barangaroo Avenue',
 'algorithm': None,
 'annualHoldingsTurnover': None,
 'annualReportExpenseRatio': None,
 'ask': 4.45,
 'askSize': 1100,
 'averageDailyVolume10Day': 221412,
 'averageVolume': 69157,
 'averageVolume10days': 221412,
 'beta': 1.709883,
 'beta3Year': None,
 'bid': 4.11,
 'bidSize': 1000,
 'bookValue': 2.94,
 'category': None,
 'circulatingSupply': None,
 'city': 'Sydney',
 'companyOfficers': [],
 'country': 'Australia',
 'currency': 'USD',
 'dateShortInterest': 1593475200,
 'dayHigh': 4.89,
 'dayLow': 4.1501,
 'dividendRate': None,
 'dividendYield': None,
 'earningsQuarterlyGrowth': None,
 'enterpriseToEbitda': None,
 'enterpriseToRevenue': None,
 'enterpriseValue': 30959502,
 'exDividendDate': None,
 'exchange': 'NCM',
 'exchangeTimezoneName': 'America/New_York',
 'exchangeTimezoneShortName': 'EDT',
 'expireDate': None,
 'fiftyDayAverage': 3.4954286,
 'fiftyTwoWeekHigh': 9.74,
 'fiftyTwoWeekLow': 2.27,
 'fiveYearAverageReturn': None,
 'fiveYearAvgDividendYield': None,
 'floatShares': 4013694,
 'forwardEps': None,
 'forwardPE': None,
 'fromCurrency': None,
 'fundFamily': None,
 'fundInceptionDate': None,
 'gmtOffSetMilliseconds': '-14400000',
 'heldPercentInsiders': 0,
 'heldPercentInstitutions': 0.035639998,
 'industry': 'Biotechnology',
 'isEsgPopulated': False,
 'lastCapGain': None,
 'lastDividendValue': None,
 'lastFiscalYearEnd': 1561852800,
 'lastMarket': None,
 'lastSplitDate': 1499990400,
 'lastSplitFactor': '1:4',
 'legalType': None,
 'logo_url': 'https://logo.clearbit.com/kaziatherapeutics.com',
 'longBusinessSummary': 'Kazia Therapeutics Limited, an oncology-focused '
                        'biotechnology company, develops anti-cancer drugs. '
                        'Its lead development candidate is GDC-0084, a small '
                        'molecule, brain-penetrant inhibitor of the '
                        'PI3K/AKT/mTOR pathway, which is developed as a '
                        'potential therapy for glioblastoma. The company is '
                        'also developing Cantrixil, which is being developed '
                        'for the treatment of ovarian cancer and is in '
                        'hospitals across Australia and the United States '
                        'under an Investigational New Drug application. Kazia '
                        'Therapeutics Limited has collaboration agreements St '
                        'Jude Childrens Hospital; Dana-Farber Cancer '
                        'Institute; Alliance for Clinical Trials in Oncology; '
                        'Memorial Sloan Kettering Cancer Centre; and '
                        'University of Newcastle. The company was formerly '
                        'known as Novogen Limited and changed its name to '
                        'Kazia Therapeutics Limited in November 2017. Kazia '
                        'Therapeutics Limited was founded in 1994 and is '
                        'headquartered in Sydney, Australia.',
 'longName': 'Kazia Therapeutics Limited',
 'market': 'us_market',
 'marketCap': 29518214,
 'maxAge': 1,
 'maxSupply': None,
 'messageBoardId': 'finmb_401773',
 'morningStarOverallRating': None,
 'morningStarRiskRating': None,
 'mostRecentQuarter': 1577750400,
 'navPrice': None,
 'netIncomeToCommon': None,
 'nextFiscalYearEnd': 1625011200,
 'open': 4.19,
 'openInterest': None,
 'payoutRatio': 0,
 'pegRatio': None,
 'phone': '1300 787 272',
 'previousClose': 4.29,
 'priceHint': 4,
 'priceToBook': 1.4863945,
 'priceToSalesTrailing12Months': None,
 'profitMargins': 0,
 'quoteType': 'EQUITY',
 'regularMarketDayHigh': 4.89,
 'regularMarketDayLow': 4.1501,
 'regularMarketOpen': 4.19,
 'regularMarketPreviousClose': 4.29,
 'regularMarketPrice': 4.19,
 'regularMarketVolume': 209525,
 'revenueQuarterlyGrowth': None,
 'sector': 'Healthcare',
 'sharesOutstanding': 7216670,
 'sharesPercentSharesOut': 0.0014,
 'sharesShort': 10004,
 'sharesShortPreviousMonthDate': 1590710400,
 'sharesShortPriorMonth': 6042,
 'shortName': 'Kazia Therapeutics Limited',
 'shortPercentOfFloat': None,
 'shortRatio': 0.14,
 'startDate': None,
 'state': 'NSW',
 'strikePrice': None,
 'symbol': 'KZIA',
 'threeYearAverageReturn': None,
 'toCurrency': None,
 'totalAssets': None,
 'tradeable': False,
 'trailingAnnualDividendRate': None,
 'trailingAnnualDividendYield': None,
 'trailingEps': -0.92,
 'twoHundredDayAverage': 3.4630215,
 'volume': 209525,
 'volume24Hr': None,
 'volumeAllCurrencies': None,
 'website': 'http://www.kaziatherapeutics.com',
 'yield': None,
 'ytdReturn': None,
 'zip': '2000'}